Analyst at Oppenheimer Maintains Acceleron Pharma (NASDAQ:XLRN)Stock Rating as a 'Hold'

Ivan Schwartz
June 20, 2017

56,102 shares of the company were exchanged. It has outperformed by 7.79% the S&P500. It was reported on Jun, 19 by Barchart.com. We have $42.62 PT which if reached, will make NYSE:JWN worth $708.30 million less.

Analysts await Lion Biotechnologies Inc (NASDAQ:LBIO) to report earnings on August, 14. Moreover, Loomis Sayles Co Lp has 0.02% invested in Acceleron Pharma Inc (NASDAQ:XLRN) for 370,424 shares. Winslow Evans Crocker Incorporated holds 1,260 shares or 0% of its portfolio. Array Biopharma Inc (NASDAQ:ARRY) was reduced too. About 110,271 shares traded.

After a recent spot-check, Acceleron Pharma Inc. It has underperformed by 39.13% the S&P500.The move comes after 6 months positive chart setup for the $1.21 billion company. $54,916 worth of stock was sold by Kumar Ravindra on Wednesday, January 4. Therefore 60% are positive. On average, analysts anticipate that Acceleron Pharma will post ($2.54) earnings per share for the current fiscal year. The firm has "Outperform" rating by FBR Capital given on Friday, January 15.

03/08/2017 - UBS began new coverage on Acceleron Pharma Inc. giving the company a "buy" rating. The rating was downgraded by Oppenheimer to "Market Perform" on Tuesday, June 13. Novo A S invested 3.01% of its portfolio in Acceleron Pharma Inc (NASDAQ:XLRN). The stock of Acceleron Pharma Inc (NASDAQ:XLRN) has "Outperform" rating given on Monday, February 1 by Oppenheimer. The firm earned "Outperform" rating on Tuesday, December 13 by Oppenheimer. The rating was initiated by Citigroup with "Neutral" on Thursday, September 29.

Since January 4, 2017, it had 0 buys, and 5 selling transactions for $271,623 activity. $54,916 worth of Acceleron Pharma Inc (NASDAQ:XLRN) shares were sold by Sherman Matthew L. MCLAUGHLIN KEVIN F sold $46,667 worth of stock. Tudor Investment Corp Et Al now owns 8,389 shares of the biopharmaceutical company's stock worth $214,000 after buying an additional 1,631 shares in the last quarter. 1,700 shares were sold by MCLAUGHLIN KEVIN F, worth $46,667 on Wednesday, January 4. These shares are worth $54,920 and were traded at $27.46 each.

Institutional investors now hold around $1.01 billion or 94.5% in XLRN stock. Its up 0.35, from 1 in 2016Q3.

James McAvoy Busts Out His Razor for New 'X-Men' Movie
Lilanda will lead the quest to imprison and execute the Dark Phoenix , which sends her into conflict with the X-Men. We'll find out exactly what the new film entails from November 2, 2018, when Dark Phoenix opens in theaters.

RSP Permian's (RSPP) "Overweight" Rating Reiterated at Barclays PLC
In other news, Director Ted Collins, Jr. sold 42,000 shares of the business's stock in a transaction on Thursday, June 8th. Moreover, Balyasny Asset Limited Liability Corp has 0.04% invested in RSP Permian Inc (NYSE:RSPP) for 156,792 shares.

Cristiano Ronaldo skips post-match press conference after Portugal draw
It was harsh on Mexico who had done most of the running, but Portugal have mastered the art of striking on the break. But Mexico responded with Hernandez testing Portugal keeper Rui Patricio, before putting his side level.

Taking a closer look into the volatility on shares of Acceleron Pharma Inc. 25 funds opened positions while 49 raised stakes. Manufacturers Life Insurance The holds 19,341 shares. Principal Financial Group reported 105,742 shares or 0% of all its holdings. Deutsche Bancorporation Ag holds 0.01% or 281,887 shares. Eventide Asset Limited Liability reported 0.71% in Acceleron Pharma Inc (NASDAQ:XLRN). Blackrock Group Inc Limited holds 276,525 shares. Capital Fund Mngmt Sa holds 0% or 19,496 shares in its portfolio. Sei Invests stated it has 300 shares or 0% of all its holdings. State Board Of Administration Of Florida Retirement holds 0% of its portfolio in Acceleron Pharma Inc (NASDAQ:XLRN) for 18,198 shares. Fmr Lc accumulated 5.24M shares. Sphera Funds Management, a Israel-based fund reported 100,000 shares. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.58) by $0.08. FBR & Co restated a "buy" rating on shares of Acceleron Pharma in a research report on Saturday, April 8th. Thompson Davis & stated it has 0.02% of its portfolio in Acceleron Pharma Inc (NASDAQ:XLRN).

Investors sentiment decreased to 0.81 in Q4 2016. Its up 0.35, from 1 in 2016Q3. Blackrock stated it has 0% of its portfolio in Ambarella Inc (NASDAQ:AMBA). Tekla Mgmt Limited Liability Company accumulated 54,450 shares or 0.06% of the stock. Guggenheim Limited Liability owns 66,406 shares. (NYSE:JWN) for 5,657 shares. State Of Wisconsin Invest Board invested in 0.03% or 145,644 shares. Virtu Finl Inc was reduced too. During the same quarter previous year, the company posted $0.13 EPS. The Neuberger Berman Group Llc holds 4.07M shares with $183.89 million value, up from 4.06M last quarter. Creative Planning reported 1,000 shares stake. 500,337 were reported by Qvt Fin Limited Partnership. Highbridge Cap Mgmt Ltd Liability Corp holds 0.01% or 18,092 shares in its portfolio. South Dakota-based South Dakota Inv Council has invested 0.05% in Nordstrom, Inc.

Since January 1, 0001, it had 1 insider buy, and 0 sales for $28,000 activity. NORDSTROM PETER E also sold $69,319 worth of Nordstrom, Inc. The insider Ertel Steven D sold $68,611.

Nordstrom, Inc.is a fashion specialty retailer in the United States. The third largest holder is Blackrock Inc., which now holds $109.1 million worth of this stock and that ownership represents almost 9.49% of its market capitalization. The Company's divisions include Retail and Credit. It has a 33.53 P/E ratio. As of March 20, 2017, the Company operated 344 the United States stores located in 40 states as well as an e-commerce business.

Among 11 analysts covering Quanta Services Inc. Novo A S now owns 1,240,173 shares of the biopharmaceutical company's stock valued at $31,649,000 after buying an additional 336,340 shares in the last quarter. Therefore 100% are positive. First Financial Bankshares had 8 analyst reports since July 17, 2015 according to SRatingsIntel. The rating was upgraded by Citigroup on Thursday, March 2 to "Buy". Macquarie Research maintained the shares of FFIN in report on Friday, October 23 with "Neutral" rating. UBS maintained Nordstrom, Inc. Oppenheimer has "Buy" rating and $4000 target.

Other reports by GizPress

Discuss This Article

FOLLOW OUR NEWSPAPER